Russia receives renewed approval for COVID-19 vaccine trials in India -RDIF

Modesto Morganelli
Ottobre 17, 2020

On August 11, 2020, Sputnik V, developed by the Gamaleya National Center of Epidemiology and Microbiology, was registered by the Ministry of Health of Russian Federation and became the world's first registered vaccine against Covid-19 based on the human adenoviral vectors platform. Worldwide, about 40 vaccine candidates are in the race of vaccination. The vaccine named EpiVacCorona comes after Russian Federation recently granted similar approval to its first COVID-19 vaccine named Sputnik V.

BBIBP-CorV is one of at least 10 coronavirus vaccine projects globally to have entered Phase 3 trials, four of which are led by Chinese scientists, according to the World Health Organisation. Proven success factors of H1N1 and Ebola have turned out as guiding principles in COVID-19 vaccine development.

India's coronavirus infections rose by another 62,212 cases over the previous day and a local media report said on Saturday that the government had begun identifying about 300 million people who would be given the vaccine first when it is ready. "This is a significant development that allows us to commence the clinical trial in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic", said G V Prasad, co-chairman and managing director, Dr Reddy's Laboratories.

The Prime Minister is said to have told the meeting that the cooperation should be not restricted to the immediate neighbourhood; instead, India should reach out the entire world, with vaccines, medicines and IT platforms for vaccine delivery system.

Officials in Jiaxing city said yesterday (Oct 15) residents aged between 18 and 59 with "urgent needs" can seek consultations at clinics for a Sinovac Biotech vaccine that authorities have been giving to groups such as medical workers. "Thereafter, we will produce more and more dosages by the permission of the government", added Dr Jadav. However, the biggest challenge lies in its accessibility. "Effective governance is also required to carry out the judicious accessibility of the vaccine, which we have already". In comments to the media, scientists developing the vaccine said that it produced enough antibodies to protect the person who had it from the virus and that the immunity it creates could last for up to six months.

We need to persevere and wait a little while longer. As estimated 60 crore vaccine doses would be administered to them. "Ensuring accessibility for 80 per cent of the population is a huge task indeed".

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE